Expert Interview
A Second Opinion: Reviewing the potential of AAV-GAD, a gene therapy from MeiraGTx for the treatment of Parkinson's Disease
Ticker(s): MGTXInstitution: Montefiore Medical Center
- Director, Division of Movement Disorders and Assistant professor of Neurology at Albert Einstein College of Medicine
- Sees 220 patients with Parkinson's Disease yearly
- Clinical interest and contributor to journal articles and book chapters on a variety of neurologic topics
How many patients do you manage with Parkinson's?
Added By: ben_adminWhat are your thoughts on the potential of AAV-GAD?
Added By: ben_adminDescribe your background and current practice setting. How many patients with PD do you manage?
Added By: ben_adminWhat are the current treatment options for Parkinson's disease, and how effective are they in managing symptoms, especially as the disease progresses?
Added By: catalin_adminWhat are the primary unmet needs in Parkinson's treatment, and could gene therapy like AAV-GAD fulfill these gaps by altering the disease's progression or providing new symptomatic relief?
Added By: catalin_adminHow does the administration of AAV-GAD (bilateral infusion into the subthalamic nucleus) compare to deep brain stimulation (DBS) in terms of procedure complexity, patient perception, and potential barriers?
Added By: catalin_adminWhat are the safety and tolerability concerns related to AAV-GAD, and what kind of data or longer-term effects would experts like to see in future trials to ensure its viability?
Added By: catalin_adminWho would be considered the ideal candidate for AAV-GAD, and what factors would influence the choice between this gene therapy and existing treatments like DBS?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
